Navigation Links
New Study Shows Isolaz Can Reduce Acne Up to 90 Percent
Date:2/1/2008

Journal of Drugs in Dermatology Publishes Safety and Efficacy of Acne

Treatment

SANTA MONICA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Southern California-based dermatologist Ava Shamban, MD and co-investigators Mikiko Enokibori, MD, and Vic Narurkar, MD, conducted a global multi-center study using Isolaz to treat patients suffering from various degrees of acne, ranging from mild and moderate inflammatory acne to severe nodular and cystic acne.

The February edition of the Journal of Drugs in Dermatology will report the results of this study using the Isolaz device (Aesthera Corp(TM), Pleasanton, CA) for the treatment of mild to severe acne.

Prospective and retrospective data was collected from 56 patients who had undergone two to four treatments with a photopneumatic device (Isolaz). Evaluation criteria included lesion counts, using blinded physician evaluations of acne clearance, as well as treatment satisfaction surveys given to the participating physicians and patients.

In this study, 23 percent of patients had mild acne, 23 percent had moderate acne, 31 percent had severe nodular acne, and 8 percent had severe cystic acne. Results of the study demonstrated a 50 percent improvement in lesion counts post first treatment and a 90 percent improvement in lesion counts after the fourth treatment. Median acne severity (Burton Scale) decreased from level 4 before treatment to level 2 after final treatment. Median acne improvement was 4.5 (scale 1 - 5), and median acne clearance was 3 (scale 1 - 4). Erythema ratings decreased significantly with subsequent treatments and clinically significant adverse events were not reported. Both physician and patient satisfaction was high and increased with number of treatments given throughout the trial.

"The Isolaz system powered by photopneumatic technology provides severe acne sufferers with a safe and effective treatment option without the potential side effects associated with drug-based treatment alternatives," explains Dr. Shamban.

The unique mechanism of photopneumatic technology combines the proven therapeutic qualities of broadband light with pneumatic energy to physically evacuate the sebaceous gland. Dislodging the follicular ostia results in an almost immediate clearance of lesions 24 - 48 hours post treatment.

"Patients notice immediate improvement of acne that is not attainable with traditional medical therapies," notes co-investigator Dr. Narurkar. "In addition, painless and quick treatments with continued long-term improvement differentiate Isolaz treatments from other device-based treatments while contributing to high patient satisfaction levels," he adds.

About Ava T. Shamban, MD

Ava T. Shamban is Director of the Laser Institute for Dermatology and European Skin Care and assistant clinical professor at UCLA. For more about Dr. Shamban, visit: http://www.shamban-md.com

About Vic A. Narurkar, MD

Dr. Vic Narurkar is founder of the Bay Area Laser Institute in San Francisco, CA and assistant clinical professor at UC Davis. For more about Dr. Narurkar, visit: http://www.BayAreaLaserDr.com

About Mikiko Enokibori, MD

Dr. Mikiko Enokibori is founder of Mizuki Clinic in Otsu City, Shiga, Japan. For more about Dr. Enokibori, visit http://www.mizuki-clinic.com

About Isolaz

Isolaz is a painless device-based acne treatment powered by a breakthrough technology called photopneumatics (photo = light-based; pneumatics = vacuum) that combines vacuum with broadband light. Isolaz is the only device FDA cleared for the treatment of mild to moderate acne, including pustular and comedonal acne as well as mild to moderate inflammatory acne (acne vulgaris). Additionally, studies demonstrate that Isolaz treatments result in an immediate drying and flattening of lesions within 24 to 48 hours of treatment.

For more information about Isolaz treatments, visit http://www.Isolaz.com.


'/>"/>
SOURCE Ava Shamban, MD
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Journal Sleep: Study concludes a daytime nap can benefit a persons memory performance
2. MITs McGovern Institute researchers awarded $8.5M to study brain basis of autism and dyslexia
3. Study Spots Gene That Plays Role in Infertility
4. Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
5. Top hospitals have 27 percent lower mortality, annual HealthGrades study finds
6. Study reveals improved prediction of prostrate cancer
7. Porous structures help boost integration of host tissue with implants, study finds
8. UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets
9. Study paves way for development of macular degeneration cures
10. Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals
11. Samarion(SM) Announces Formation of Outcome Based Study Team for Industrys Only Enterprise Quality Improvement System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 ... gadget will continue to be available at a discounted crowdfunding price on Indiegogo ... wherever they are, I also wanted to bring a fidget toy to the market ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, ... is located on more than four acres of land at 5620 Sohl Avenue in ... The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of the private ...
(Date:5/26/2017)... San Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... San Francisco, is proud to announce a new, informational blog post on insurance options. ... tooth surgery, checking insurance plans may help save time and money. Visiting an in-network ...
(Date:5/26/2017)... ... ... Cross”: the personal journey of Bob Massey and his faith in the Lord. “THE ... Massey. Bob Massey is small in stature but big in character. As Johnny ... others is apparent in all of his life decisions. , “I’m in the eightieth ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... COTTAGE, N.Y. , May 22, 2017 /PRNewswire/ ... antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of a ... plain English, the results of a clinical study ... one year treatment with Gene-Eden-VIR/Novirin in individuals suffering ... important to note that there are no other ...
(Date:5/18/2017)... -- Two Bayer U.S. Pharmaceutical leaders received top awards from ... th Woman of the Year event ... mission of furthering the advancement and impact of women ... Powell-Steffen , senior director of brand activation and inside ... Howe , a regional business manager for New England ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
Breaking Medicine Technology: